Lyell Immunopharma Inc (LYEL)
1.28
+0.16
(+14.29%)
USD |
NASDAQ |
Nov 04, 16:00
1.31
+0.03
(+2.34%)
After-Hours: 07:22
Lyell Immunopharma Revenue (Quarterly): 0.013M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.013M |
| March 31, 2024 | 0.003M |
| December 31, 2023 | 0.013M |
| September 30, 2023 | 0.025M |
| June 30, 2023 | 0.027M |
| March 31, 2023 | 0.065M |
| December 31, 2022 | 48.39M |
| September 30, 2022 | 0.003M |
| June 30, 2022 | 35.74M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.553M |
| December 31, 2021 | 2.822M |
| September 30, 2021 | 2.755M |
| June 30, 2021 | 2.628M |
| March 31, 2021 | 2.445M |
| December 31, 2020 | 2.312M |
| September 30, 2020 | 1.07M |
| June 30, 2020 | 3.118M |
| March 31, 2020 | 1.256M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.003M
Minimum
Sep 2022
48.39M
Maximum
Dec 2022
5.735M
Average
1.163M
Median
Revenue (Quarterly) Benchmarks
| Ocular Therapeutix Inc | 16.44M |
| Marinus Pharmaceuticals Inc | 8.056M |
| NovaBay Pharmaceuticals Inc | 2.40M |
| Palatin Technologies Inc | 0.35M |
| iBio Inc | 0.175M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -45.81M |
| Total Expenses (Quarterly) | 51.54M |
| EPS Diluted (Quarterly) | -0.18 |
| Enterprise Value | -163.44M |
| Profit Margin (Quarterly) | -352.4K% |
| Earnings Yield | -64.06% |
| Normalized Earnings Yield | -60.07 |